## Abstract ## Objective To investigate patient predictors of response to treatment of Major Depressive Episode (MDE) in Alzheimer's disease (AD). ## Methods Fortyβfour outpatients with AD and MDE were randomized to receive either sertraline or placebo in a 12βweek placeboβcontrolled, flexibleβd
Cognitive Response to Pharmacological Treatment for Depression in Alzheimer Disease: Secondary Outcomes From the Depression in Alzheimer's Disease Study (DIADS)
β Scribed by Munro, Cynthia A.; Brandt, Jason; Sheppard, Jeannie-Marie E.; Steele, Cynthia D.; Samus, Quincy M.; Steinberg, Martin; Rabins, Peter V.; Lyketsos, Constantine G.
- Book ID
- 123371361
- Publisher
- American Psychiatric Publishing Inc
- Year
- 2004
- Tongue
- English
- Weight
- 112 KB
- Volume
- 12
- Category
- Article
- ISSN
- 1064-7481
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Objective: To determine if the effect of sertraline in the depression in alzheimer's disease study - 2 (diads-2) differed in subgroups of patients defined by baseline depression criteria. ## Methods: Diads-2 was a randomized, parallel, placebo-controlled, multicenter trial designed to evaluate
## Abstract ## Context Major depression affects about 25% of patients with Alzheimer's disease (AD) and has serious adverse consequences for patients as well as caregivers. Studies of treatments for depression in AD, like most treatment studies, depend on the ability of the scales used to measure